Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AltSonflex1-2-3 Shigella vaccine long-term immunogenicity follow-up in African children
NCT07320716Phase 2Not yet recruiting
- Sponsor
- GSK
- Start
- Jan 2026
- Primary completion
- Oct 2028
- Modality
- Vaccines & Immunotherapeutics
01
Overview
A Phase 2 trial of altSonflex1-2-3 in shigellosis, sponsored by GSK. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
altSonflex1-2-3
03
Conditions
shigellosis
Beyond the preview
Go deeper on NCT07320716.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07320716.